Page last updated: 2024-08-26

fulvestrant and crizotinib

fulvestrant has been researched along with crizotinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Alhusban, A; Alkhalifa, AE; Ayoub, NM; Ibrahim, DR	1

Other Studies

1 other study(ies) available for fulvestrant and crizotinib

Article	Year
Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor. Medical oncology (Northwood, London, England), 2021, Jan-15, Volume: 38, Issue:1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Estrogen Receptor alpha; Fulvestrant; Humans; Inhibitory Concentration 50; Ki-67 Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Tamoxifen	2021

Article

Year

Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.

Medical oncology (Northwood, London, England), 2021, Jan-15, Volume: 38, Issue:1

Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Estrogen Receptor alpha; Fulvestrant; Humans; Inhibitory Concentration 50; Ki-67 Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Tamoxifen

2021